ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Clinical Trial
Official title:
LLME Treated Cellular Immunotherapy Following T-cell Depleted Allogeneic Heamtopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution
The purpose of this study is to determine if pre-treating donor lymphocytes with an investigational drug known as L-leucyl-L-leucine methyl ester (LLME, prior to donor lymphocyte infusion (DLI) will improve the recovery of the immune system following stem cell transplant.
If you agree to participate in this research study you will be evaluated during the 4th-6th
week after your transplant to determine the number of CD4 cells in your circulation and to
determine that your body has eliminated all of the immune suppressing medicines used around
the time of your transplant. This will be performed by studying the cells from two tubes of
blood. Thereafter, blood cells will be obtained from your donor (the same donor as used for
the transplant). These cells from the donor will be treated with LLME in the laboratory. The
cells will then be washed to eliminate the LLME, counted, and the desired number will be
administered to you by transfusion.
Four to six weeks later, you will have additional blood drawn (2-3 teaspoons) to determine
the number of CD4 cells in your blood. If the number is below 100, you will be given another
transfusion of LLME treated cells, but you will receive a larger number of cells. Above 100
CD4 cells, the risk of infections appears to decrease. This will be repeated every 8 weeks
provided that you and your donor remain willing to continue until one of three things
happens. The three things that would cause us to stop further DLI would be: (1) you develop
a CD4 count of over 100, (2) you develop evidence of GVHD, or (3) we reach the maximum
practical number of cells which your donor could provide.
Your donor will also be reevaluated by medical history, physical examination, and blood
tests to ensure that he/she remains healthy and can undergo the cell donation procedure
safely. He or she will donate the first doses of white cells by drawing a small amount of
blood. Later donations, if necessary, will be collected in a manner that is very similar to
how platelets are normally collected from volunteer donors by the blood bank. The manner in
which the transfusions are given will be similar to that in which you have received red
blood cell and platelet transfusions in the past.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03294824 -
Non Randomized Comparative Study With Control
|
||
Recruiting |
NCT04098653 -
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT03256071 -
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02653196 -
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 | |
Recruiting |
NCT04123392 -
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT05596968 -
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
|
||
Recruiting |
NCT05596981 -
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
|
||
Recruiting |
NCT05601895 -
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
|
||
Recruiting |
NCT03357172 -
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT04995653 -
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
|
Phase 1 | |
Completed |
NCT02250300 -
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Recruiting |
NCT03593161 -
Humor Therapy and Distress After Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05379569 -
Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL
|
Phase 4 | |
Not yet recruiting |
NCT03902041 -
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT
|
||
Completed |
NCT02270346 -
Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
|
N/A | |
Recruiting |
NCT03297528 -
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
|
Phase 2 | |
Completed |
NCT01879072 -
Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)
|